Cargando…
Targeting interleukin 4 receptor α: A new approach to the treatment of cutaneous autoimmune bullous diseases?
Bullous pemphigoid, mucous membrane pemphigoid, and pemphigus vulgaris are different cutaneous autoimmune blistering diseases, with complex pathogenic mechanisms. In all of them, a type‐2 response is thought to have a central role. Interleukin 4 and Interleukin 13 are crucial cytokines in type‐2 res...
Autores principales: | Russo, Roberto, Cozzani, Emanuele, Gasparini, Giulia, Parodi, Aurora |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons, Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7154653/ https://www.ncbi.nlm.nih.gov/pubmed/31863534 http://dx.doi.org/10.1111/dth.13190 |
Ejemplares similares
-
Absolving COVID-19 Vaccination of Autoimmune Bullous Disease Onset
por: Russo, Roberto, et al.
Publicado: (2022) -
May bullous pemphigoid be worsened by COVID-19 vaccine?
por: Cozzani, Emanuele, et al.
Publicado: (2022) -
Use of Dupilumab in Bullous Pemphigoid: Where Are We Now?
por: Russo, Roberto, et al.
Publicado: (2022) -
Considerations on SARS-CoV-2 vaccines in patients with autoimmune blistering diseases
por: Cozzani, Emanuele, et al.
Publicado: (2021) -
Editorial: Autoimmune blistering diseases: advances in the understanding of pathogenesis and new therapeutic horizons
por: Gasparini, Giulia, et al.
Publicado: (2023)